General Information |
| Summary |
This is a single center, single arm and open-label study to investigate the safety and efficacy of iPS-NCS with Parkinson's Disease. |
| Clinical trials phase |
Other |
| Start date (estimated) |
2019-02-01 |
| End date (estimated) |
2021-02-01 |
| Clinical feature |
| Label |
Parkinson's disease |
| Link |
http://purl.obolibrary.org/obo/DOID_14330 |
| Description |
A synucleinopathy that has_material_basis_in degeneration of the central nervous system that often impairs motor skills, speech, and other functions.; Xref MGI. OMIM mapping confirmed by DO. [SN]. |
|
Administrative Information |
| NCT number |
NCT03815071 |
| ICTRP weblink |
https://trialsearch.who.int/Trial2.aspx?TrialID=NCT03815071 |
| Other study identifiers |
|
| Source weblink |
https://clinicaltrials.gov/show/NCT03815071 |
| Sponsors |
Allife Medical Science and Technology Co., Ltd.
|
Cells |
| Which differentiated cell type is used |
| Label |
neural stem cell |
| Link |
http://purl.obolibrary.org/obo/CL_0000047 |
| Description |
An undifferentiated neural cell that originates from the neuroectoderm and has the capacity both to perpetually self-renew without differentiating and to generate multiple central nervous system neuronal and glial cell types. |
|
Recruitment |
| Recruitment Status |
Not yet recruiting |
| Estimated number of participants |
10 |
